<DOC>
	<DOCNO>NCT01161498</DOCNO>
	<brief_summary>This study conduct learn safety risk use talimogene laherparepvec treat patient head neck cancer see talimogene laherparepvec chemoradiation together destroy tumour versus use chemoradiation alone . This study may provide information usefulness talimogene laherparepvec combine chemoradiation future treatment head neck cancer .</brief_summary>
	<brief_title>Study Safety Efficacy Talimogene Laherparepvec With Cisplatin Radiotherapy Treatment Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>The objective evaluate efficacy safety treatment chemoradiation ( CRT ) plus talimogene laherparepvec compare CRT alone previously untreated patient locally advance squamous cell carcinoma head neck ( SCCHN ) surgical resection clinical indicate . The efficacy endpoint study aim demonstrate overall clinical benefit patient treat talimogene laherparepvec compare CRT alone .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Male female ≥ 18 year 2 . Eastern CoOperative Oncology Group ( ECOG ) Performance Status ≤ 1 3 . Histological evidence ( primary lesion and/or lymph node ) squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx 4 . Stage III IV disease ( T2N23M0 , T34N13M0 ) 5 . No evidence distant metastasis compute tomography ( CT ) positron emission tomography ( PET ) /CT scan 6 . Life expectancy &gt; 4 month 7 . Neutrophil count ≥ 2,000/mm^3 8 . Platelet count ≥ 100,000/mm^3 9 . Hemoglobin ≥ 10 g/dL 10 . Bilirubin ≤ 1.5 time upper limit normal ( ULN ) 11 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 time ULN 12 . Alkaline phosphatase ≤ 2.5 time ULN 13 . Creatinine clearance ≥ 60 mL/min 14 . Female patient childbearing potential ( i.e . surgically sterile , spontaneous amenorrhea least 12 month ) must agree use effective form contraception treatment phase study . 15 . Male patient must agree use condom spermicide female partner must use effective method birth control . 16 . Provide write informed consent accordance applicable regulation follow study procedure . Patients must capable understanding investigational nature , potential risk benefit study . 1 . Prior treatment locally advanced SCCHN ( No prior surgery SCCHN except nodal sample biopsy study disease ) . 2 . Patients T12N1 T1N23 . 3 . Preexisting peripheral neuropathy ≥ Grade 2 ( motor sensory ) . 4 . Weight loss &gt; 20 % body weight within 3 month screen ( unless purposeful ) . 5 . Surgery ≤ 28 day randomization exception feed tube placement , dental extraction , central venous catheter placement , biopsy nodal sample . 6 . Cancer nasopharynx , sinus , salivary gland skin . 7 . Previous radical radiation therapy ( RT ) head neck region , exclude superficial RT nonmelanomatous skin cancer . 8 . Prior cancer , except : diagnosed &gt; 5 year ago evidence disease recurrence clinical expectation recurrence le 5 % ; successfully treat nonmelanoma skin cancer ; carcinoma situ cervix . 9 . Significant intercurrent illness interfere chemotherapy radiation therapy human immunodeficiency ( HIV ) infection , cardiac failure , pulmonary compromise ( chronic obstructive pulmonary disease , pneumonia respiratory decompensation ) result hospitalization within 12 month screen , active infection . 10 . Any significant cardiac disease ( e.g. , New York Heart Association ( NYHA ) Class 3 4 ; myocardial infarction within past 6 month ; unstable angina ; coronary angioplasty coronary artery bypass graft ( CABG ) within past 6 month ; uncontrolled atrial ventricular cardiac arrhythmias.. 11 . High risk poor compliance therapy follow assess investigator . 12 . Active herpes labialis , lesion due herpes simplex virus type I ( HSV1 ) dermatoses involve within 50 cm lesion inject ; active HSV1 lesion must resolve talimogene laherparepvec inject . 13 . Prior systemic chemotherapy type cancer . 14 . Patients radiation therapy contraindicate . 15 . Pregnant breastfeed female . Confirmation woman childbearing potential pregnant . A negative serum β human chorionic gonadotropin ( βhCG ) pregnancy test result must obtain screening period . 16 . Currently enrol receive investigational agent clinical research study receive investigational agent reason within 4 week prior screen . 17 . Require intermittent chronic treatment antiherpetic drug ( e.g. , acyclovir ) , intermittent topical use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>squamous cell</keyword>
	<keyword>OncoVEX^GM-CSF</keyword>
	<keyword>Oncovex</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>Cisplatin</keyword>
</DOC>